
FDA Approvals in Oncology: January-March 2025
In the first quarter of 2025, the FDA issued 13 approvals for oncology treatments, covering nine types of cancer...
In the first quarter of 2025, the FDA issued 13 approvals for oncology treatments, covering nine types of cancer...
This Trojan horse-like treatment strategy may help neutralize undruggable cancer drivers.
Researchers are finding early clinical success in developing more targeted treatments for bile duct cancer, also called cholangiocarcinoma.
During late spring and early summer, the U.S. Food and Drug Administration (FDA) approved four new molecularly targeted therapeutics—alpelisib...
On Monday, the U.S. Food and Drug Administration (FDA) announced the highly anticipated approval of the molecularly targeted therapeutic...
Last week saw a flurry of new anticancer therapeutics approved by the U.S. Food and Drug Administration (FDA) for...
Recently, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic vemurafenib (Zelboraf) for treating certain adults...
Last week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic acalabrutinib (Calquence) for treating adults...
This week’s excitement surrounding the groundbreaking U.S. Food and Drug Administration (FDA) approval of the CAR T–cell therapy tisagenlecleucel...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called neratinib (Nerlynx)...